Potent CDK9 inhibitor shows promise for overcoming drug resistance in hematological malignancies. Your friend's email. Your email. I would like to subscribe to Science X Newsletter.

GFH375 is an orally bioavailable, highly selective and potent KRAS G12D inhibitor targeting both “ON” (GTP-bound) and “OFF” (GDP-bound) states. Here we report the preliminary results of GFH375 in ...

TT-00973-MS is a highly selective and potent AXL inhibitor which exhibited significant anti-tumor activities in both SK-OV-3 and H1299 derived CDX model with AXL over-expression. Here is first time to ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).

“We are thrilled to bring forward the first phase 3 results from our clinical development program evaluating enlicitide, which, if approved, would be the first marketed oral PCSK9 inhibitor in ...

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic Published May 29, 2025 9:00am EDT ...

Cyclin dependent kinases are a key family of kinases involved in cell cycle regulation and are an attractive target for cancer chemotherapy. The roles of four residues of the cyclin-dependent kinase ...